NCT06282692 - INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

May 19, 2024

Study Completion Date

July 19, 2024

Conditions

COVID-19 PandemicCOVID-19 Vaccines

Interventions

BIOLOGICAL

INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg

Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.

Trial Locations (1)

RECRUITING

Dr. Soetomo General Hospital, Surabaya